Continuous glucose monitoring reported to improve lives for type 2 diabetes
Based on the mean difference between groups taking part in the study after 12 months of follow-up tests, and the average HbA1c in the study being 8.27%, HbA1c was reduced by 0.56% in the group of rtCGM users.
The researchers monitored for severe hypoglycaemia – where sugar levels drop too low and third-party intervention is required - and hyperglycaemia – where sugar levels rise too high – or hospitalisation events, and the mean adjusted difference after 12 months follow-up was 0 events for people using rtCGM and 4 hypoglycaemia and 2.5 hyperglycaemia events for people using finger-pricking per 100 patient years.
Ben Byrne, Country Director of Dexcom in the UK and Ireland, said: “As healthcare technology – such as Dexcom’s rtCGM Systems – continue to evolve, policymakers have a tremendous opportunity to re-evaluate the standard of care offered to the diabetes community. Dexcom rtCGM has enormous value, not only in how it can improve quality of life for people managing diabetes, but also because it is likely to save the NHS money.”
The annual cost of diabetes to the NHS in 2022 was estimated at £10 billion – around 10% of its budget.
Mr Byrne added: “Our recent analysis clearly adds to the evidence that rtCGM is not only a highly cost-effective intervention for people with diabetes compared to finger pricking but is also likely to be cost saving. Given these findings, and with diabetes being so costly to healthcare providers in the UK, we need to take action and mandate more effective glucose monitoring consistently across the NHS and in the UK.”
Read the report in Diabetes Therapy
I would like to make a regular donation of
I would like to make a single donation of